|
시장보고서
상품코드
2084674
암태아성 항원(CEA) 시장 : 제품별, 기술별, 용도별, 최종사용자별, 지역별Carcinoembryonic Antigen (CEA) Market, By Product, By Technology, By Application, By End User, By Geography |
||||||
암태아성 항원(CEA) 시장은 2026년에 12억 8,640만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 20억 7,180만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 7.1%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 12억 8,640만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 7.10% | 2033년 시장 규모 예측 : | 20억 7,180만 달러 |
세포 접착 기능으로 알려진 당단백질인 암 태아 항원(CEA)은 종양학 분야에서 가장 오래전부터 알려져 온 종양 바이오마커 중 하나입니다. 이 특정 분자는 배아 발생기에만 발현되지만, 대장암, 폐암, 유방암, 췌장암 등 특정 암 유형와 일부 소화기 계통 암, 그 밖의 다양한 유형의 암에서 다시 발현되어 증식합니다. 전 세계 암태아성 항원(CEA) 시장에는 암 진단, 경과 관찰, 재발 추적을 목적으로 혈액, 소변, 조직 검체 내의 CEA 농도를 확인 및 정량할 수 있는 다양한 진단 키트, 진단 기기, 화학 시약, 분석 툴이 포함됩니다. 또한 암 바이오마커의 농도를 모니터링할 수 있는 그 밖의 분석 장비도 포함됩니다.
암 질환에 대한 인식과 이해가 높아지고, 초기 단계에서 바이오마커 검출법의 활용이 확대되는 세계적인 추세가 이 시장의 성장을 이끌고 있습니다. CLIA(화학발광 면역분석법), ELISA(효소면역분석법), ECL(전기화학발광법)과 같은 면역분석 기술의 비약적인 발전은 물론, 의료 시설의 확충이 점차 진행되고 있으며, 정밀 의료 프로그램의 도입이 확대되고 있는 점도 체외진단(IVD) 분야 전체의 성장을 이끌고 있습니다.
시장 역학
전 세계 암 태아 항원(CEA) 시장은 대장암, 위암, 유방암, 폐암 및 기타 암의 높은 발병률과 유병률에 힘입어 성장하고 있으며, 그 결과 선별 검사, 진단, 병기 분류, 치료 모니터링, 재발 평가를 위한 종양 바이오마커에 대한 수요가 증가하고 있습니다. 이러한 성장 요인 외에도, 맞춤형 치료 및 표적 치료의 확대, ECL 및 CLIA와 같은 자동 면역 분석기에 대한 수요 증가, 그리고 바이오마커 개발의 진전이 시장 도입을 지원하고 있습니다. 또한 종양 바이오마커 및 동반 진단의 개발 분야에서 이루어진 기술적 진보에 힘입어, 임상 현장에서 CEA 분석법의 도입이 확대되고 있습니다.
그러나 시장에는 몇 가지 제약이 존재합니다. 예를 들어 독립적인 바이오마커로서의 암 태아 항원(CEA)의 낮은 특이도, 첨단 진단 시스템에 따른 높은 비용, 규제상 과제, 그리고 분석법의 표준화와 관련된 문제 등을 들 수 있습니다. 그럼에도 불구하고 다중 바이오마커 진단 패널에 대한 관심 증가, 현장 진단 시장의 급속한 확대, 체액 생검 기술에 대한 투자, 그리고 특히 개발도상국에서의 암 검진 프로그램 확대는 암 태아 항원(CEA) 시장에 새로운 성장 기회를 가져다줄 것입니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략)를 바탕으로 전 세계 암 태아 항원(CEA) 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 암 태아 항원(CEA) 시장 보고서'는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 암 태아 항원(CEA) 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 암태아성 항원(CEA) 시장 : 제품별, 2021-2033년
제5장 세계의 암태아성 항원(CEA) 시장 : 기술별, 2021-2033년
제6장 세계의 암태아성 항원(CEA) 시장 : 용도별, 2021-2033년
제7장 세계의 암태아성 항원(CEA) 시장 : 최종사용자별, 2021-2033년
제8장 세계의 암태아성 항원(CEA) 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고 문헌 및 조사 방법
KSA 26.07.14Carcinoembryonic Antigen (CEA) Market is estimated to be valued at USD 1,286.4 Mn in 2026 and is expected to reach USD 2,071.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,286.4 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.10% | 2033 Value Projection: | USD 2,071.8 Mn |
Carcinoembryonic antigen (CEA), a glycoprotein known for its functions in cell adhesion, stands as one of the oldest known tumor biomarkers in oncology. This particular molecule is only expressed throughout embryonic development, but it reasserts itself and proliferates in certain types of cancer, such as colorectal, lung, breast, and pancreas tumors, as well as some gastrointestinal and various other kinds of cancers. The global carcinoembryonic antigen (CEA) market involves a range of diagnostic kits, diagnostic devices, chemical reagents, and analytical tools which can identify as well as quantify the level of the CEA concentration found within blood, samples of urine and tissue for purpose of cancer diagnoses, its follow-up care and follow-up observation for recurrence. It also consists of other kinds of analytical equipment that can monitor the concentration of cancerous biomarkers.
Global trends of increasing the awareness and understanding of cancer diseases and the growing utilization of early-stage biomarker detection methods have driven this market. The market is bolstered by leaps and advances in immunoassay techniques such as CLIA (chemiluminescence immunoassay), ELISA (enzyme-linked immunosorbent assay), and ECL (electrochemiluminescence), alongside a gradual expansion in the availability of health care facilities and the implementation of precision medicine programs that, collectively, drive expansion across the in-vitro diagnostics (IVD) landscape.
Market Dynamics
The global carcinoembryonic antigen (CEA) market is driven by high global incidence and prevalence of colorectal, gastric, breast, lung and other cancers resulting in high need for tumor biomarker for screening, diagnosis, staging, therapy monitoring and recurrence assessment. Besides these growth factors, market adoption is being fueled by the growth in personalized and targeted therapy and increasing demand for automated immunoassay instruments like ECL and CLIA and increasing biomarker development. Moreover, technological advances in tumor biomarker and companion diagnostics development are expanding the adoption of CEA assay across the clinical settings.
However, a number of constraints are present in the market, such as low specificity of carcinoembryonic antigen (CEA) as an independent biomarker, high costs associated with advanced diagnosis systems, regulatory challenges and problems in standardization of assay. Nevertheless, growing interest in multi-biomarker diagnostic panel, rapid increase in the market for point of care diagnostics, investment in liquid biopsy technologies and the growing number of cancer screening programmes, especially in developing countries will offer new opportunities for growth in carcinoembryonic antigen (CEA) market.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global carcinoembryonic antigen (CEA) market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation, bioMerieux SA, Sysmex Corporation, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Fujirebio Holdings, Inc., DiaSorin S.p.A., and Boditech Med Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global carcinoembryonic antigen (CEA) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global carcinoembryonic antigen (CEA) market
Market Segmentation
- Product Insights (Revenue, USD Mn, 2021 - 2033)
- Reagents and Kits
- Instruments/Analyzers
- Consumables
- Technology Insights (Revenue, USD Mn, 2021 - 2033)
- Chemiluminescence Immunoassay (CLIA)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Electrochemiluminescence Immunoassay (ECLIA)
- Others
- Application Insights (Revenue, USD Mn, 2021 - 2033)
- Cancer Diagnosis
- Treatment Monitoring
- Recurrence Monitoring
- Research Applications
- End User Insights (Revenue, USD Mn, 2021 - 2033)
- Hospitals
- Diagnostic Laboratories
- Academic and Research Institutes
- Others
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- F.Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Siemens Healthineers AG
- Danaher Corporation
- bioMerieux SA
- Sysmex Corporation
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Fujirebio Holdings, Inc.
- DiaSorin S.p.A.
- Boditech Med Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Carcinoembryonic Antigen (CEA) Market, By Product
- Global Carcinoembryonic Antigen (CEA) Market, By Technology
- Global Carcinoembryonic Antigen (CEA) Market, By Application
- Global Carcinoembryonic Antigen (CEA) Market, By End User
- Global Carcinoembryonic Antigen (CEA) Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Industry Trends
4. Global Carcinoembryonic Antigen (CEA) Market, By Product, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Reagents and Kits
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Instruments/Analyzers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Consumables
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Carcinoembryonic Antigen (CEA) Market, By Technology, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Chemiluminescence Immunoassay (CLIA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Electrochemiluminescence Immunoassay (ECLIA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Carcinoembryonic Antigen (CEA) Market, By Application, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Cancer Diagnosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Treatment Monitoring
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Recurrence Monitoring
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Research Applications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Carcinoembryonic Antigen (CEA) Market, By End User, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Carcinoembryonic Antigen (CEA) Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- F.Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Siemens Healthineers AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Danaher Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- bioMerieux SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sysmex Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fujirebio Holdings, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- DiaSorin S.p.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boditech Med Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
